<?xml version='1.0' encoding='utf-8'?>
<document id="30648587"><sentence text="A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study."><entity charOffset="58-68" id="DDI-PubMed.30648587.s1.e0" text="quetiapine" /><entity charOffset="73-83" id="DDI-PubMed.30648587.s1.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.30648587.s1.e0" e2="DDI-PubMed.30648587.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30648587.s1.e0" e2="DDI-PubMed.30648587.s1.e1" /></sentence><sentence text="Combinations of new antidepressants like duloxetine and second-generation antipsychotics like quetiapine are used in clinical treatment of major depressive disorder, as well as in forensic toxicology scenarios"><entity charOffset="41-51" id="DDI-PubMed.30648587.s2.e0" text="duloxetine" /><entity charOffset="94-104" id="DDI-PubMed.30648587.s2.e1" text="quetiapine" /><pair ddi="false" e1="DDI-PubMed.30648587.s2.e0" e2="DDI-PubMed.30648587.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30648587.s2.e0" e2="DDI-PubMed.30648587.s2.e1" /></sentence><sentence text=" The drug-drug interaction (DDI) between quetiapine and duloxetine is worthy of attention to avoid unnecessary adverse effects"><entity charOffset="41-51" id="DDI-PubMed.30648587.s3.e0" text="quetiapine" /><entity charOffset="56-66" id="DDI-PubMed.30648587.s3.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.30648587.s3.e0" e2="DDI-PubMed.30648587.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30648587.s3.e0" e2="DDI-PubMed.30648587.s3.e1" /></sentence><sentence text=" However, no pharmacokinetic DDI studies of quetiapine and duloxetine have been reported"><entity charOffset="44-54" id="DDI-PubMed.30648587.s4.e0" text="quetiapine" /><entity charOffset="59-69" id="DDI-PubMed.30648587.s4.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.30648587.s4.e0" e2="DDI-PubMed.30648587.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30648587.s4.e0" e2="DDI-PubMed.30648587.s4.e1" /></sentence><sentence text=" In the present study, a rapid and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed for simultaneous determination of quetiapine and duloxetine in rat plasma"><entity charOffset="158-168" id="DDI-PubMed.30648587.s5.e0" text="quetiapine" /><entity charOffset="173-183" id="DDI-PubMed.30648587.s5.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.30648587.s5.e0" e2="DDI-PubMed.30648587.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30648587.s5.e0" e2="DDI-PubMed.30648587.s5.e1" /></sentence><sentence text=" A one-step protein precipitation with acetonitrile was applied for sample preparation"><entity charOffset="39-51" id="DDI-PubMed.30648587.s6.e0" text="acetonitrile" /></sentence><sentence text=" The analytes were eluted on an Eclipse XDB-C18 column using the mixture of acetonitrile and 2 mM ammonium formate containing 0"><entity charOffset="76-88" id="DDI-PubMed.30648587.s7.e0" text="acetonitrile" /><entity charOffset="93-114" id="DDI-PubMed.30648587.s7.e1" text="2 mM ammonium formate" /><pair ddi="false" e1="DDI-PubMed.30648587.s7.e0" e2="DDI-PubMed.30648587.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30648587.s7.e0" e2="DDI-PubMed.30648587.s7.e1" /></sentence><sentence text="1% formic acid at a gradient elution within 6"><entity charOffset="3-14" id="DDI-PubMed.30648587.s8.e0" text="formic acid" /></sentence><sentence text="0 min" /><sentence text=" Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384" /><sentence text="4 → 253" /><sentence text="2 for quetiapine, m/z 298"><entity charOffset="6-16" id="DDI-PubMed.30648587.s12.e0" text="quetiapine" /></sentence><sentence text="1 → 154" /><sentence text="1 for duloxetine and m/z 376"><entity charOffset="6-16" id="DDI-PubMed.30648587.s14.e0" text="duloxetine" /></sentence><sentence text="2 → 165" /><sentence text="2 for IS (haloperidol), respectively"><entity charOffset="10-21" id="DDI-PubMed.30648587.s16.e0" text="haloperidol" /></sentence><sentence text=" Good linearity was obtained in the range of 0" /><sentence text="50-100 ng/mL for quetiapine (r2 = 0"><entity charOffset="17-27" id="DDI-PubMed.30648587.s18.e0" text="quetiapine" /></sentence><sentence text="9972) and 1" /><sentence text="00-200 ng/mL for duloxetine (r2 = 0"><entity charOffset="17-27" id="DDI-PubMed.30648587.s20.e0" text="duloxetine" /></sentence><sentence text="9982) using 50 μL of rat plasma, respectively" /><sentence text=" The method was fully validated with accuracy, precision, matrix effects, recovery and stability" /><sentence text=" The validated data have met the acceptance criteria in FDA guideline" /><sentence text=" The method was applied to a pharmacokinetic interaction study and the results indicated that quetiapine had significant effect on the enhanced plasma exposure of duloxetine in rats under combination use"><entity charOffset="94-104" id="DDI-PubMed.30648587.s24.e0" text="quetiapine" /><entity charOffset="163-173" id="DDI-PubMed.30648587.s24.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.30648587.s24.e0" e2="DDI-PubMed.30648587.s24.e0" /><pair ddi="false" e1="DDI-PubMed.30648587.s24.e0" e2="DDI-PubMed.30648587.s24.e1" /></sentence><sentence text=" This study could be readily applied in therapeutic drug monitoring of major depressive disorder patients receiving such drug combinations" /><sentence text="" /></document>